INSP
Inspire Medical Systems, Inc.
$50.50
+1.35 (+2.75%)
At close · Jul 15
Market Cap
$1.46B
Shares
28,813,153
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$911.98M
+13.6%
FY2025
Net Income
$145.42M
+171.8%
FY2025
Gross Margin
85.39%
+0.7pp
FY2025
Operating Margin
5.59%
+1.1pp
FY2025
Diluted EPS
$4.89
+179.4%
FY2025
Operating Cash Flow
$116.98M
-10.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $825M – $875M | $915.25M | $911.98M | $802.8M | $624.8M | $407.86M | $233.39M | $115.38M | $82.05M | $50.59M | $28.57M | $16.43M | |
| — | $130.19M | $133.23M | $122.99M | $96.58M | $66.12M | $33.28M | $17.62M | $13.64M | $10.06M | $6.02M | $3.91M | |
| — | $785.06M | $778.76M | $679.82M | $528.22M | $341.74M | $200.12M | $97.76M | $68.41M | $40.54M | $22.55M | $12.52M | |
| — | — | 85.39% | 84.68% | 84.54% | 83.79% | 85.74% | 84.73% | 83.37% | 80.12% | 78.93% | 76.23% | |
| — | $101.19M | $103.17M | $114.13M | $116.54M | $68.65M | $37.35M | $26.09M | $12.84M | $7.39M | $6.19M | $7.09M | |
| — | $632.55M | $624.64M | $529.61M | $451.96M | $320.69M | $202.62M | $127.87M | $90.47M | $53.53M | $32.36M | $22.68M | |
| — | $16.02M | $13.96M | $6.55M | $2.85M | $1.86M | $1.22M | $840K | $495K | $393K | $285K | $103K | |
| — | $627.05M | — | — | $568.49M | $389.33M | $239.97M | $153.97M | $103.3M | $60.92M | $38.55M | $29.78M | |
| — | $51.32M | $50.95M | $36.08M | -$40.27M | -$47.59M | -$39.85M | -$56.21M | -$34.9M | -$20.38M | -$16M | -$17.25M | |
| — | — | 5.59% | 4.49% | -6.45% | -11.67% | -17.07% | -48.72% | -42.53% | -40.28% | -56.02% | -105.03% | |
| — | $67.34M | $64.91M | $42.63M | -$37.43M | -$45.73M | -$38.63M | -$55.37M | -$34.4M | -$19.99M | -$15.72M | -$17.15M | |
| — | — | $137K | $22K | $0 | $1.68M | $2.13M | $2.12M | $2.12M | $3.3M | $1.75M | $1.3M | |
| — | $102K | — | — | — | — | $125K | $1.09M | $3.8M | $1.87M | $203K | $57K | |
| — | $13.94M | $14.74M | $22.37M | $20.37M | $3.32M | -$2.12M | -$880K | $1.69M | -$1.45M | -$1.51M | -$1.28M | |
| — | $63.94M | $65.7M | $58.45M | -$19.91M | -$44.27M | -$41.97M | -$57.09M | -$33.2M | -$21.83M | -$17.51M | -$18.53M | |
| — | -$67.2M | -$79.73M | $4.94M | $1.25M | $613K | $72K | $115K | $40K | $0 | $0 | $0 | |
| — | $131.14M | $145.42M | $53.51M | -$21.15M | -$44.88M | -$42.04M | -$57.2M | -$33.24M | -$21.83M | -$17.51M | -$18.53M | |
| — | — | 15.95% | 6.67% | -3.39% | -11% | -18.01% | -49.58% | -40.52% | -43.14% | -61.3% | -112.79% | |
| — | $130.56M | $145.35M | $53.25M | -$20.27M | -$44.91M | -$42.13M | -$57.28M | -$33.09M | -$21.88M | -$17.51M | -$18.53M | |
| USD/shares | — | — | $4.95 | $1.80 | -$0.72 | -$1.60 | -$1.54 | -$2.19 | -$1.40 | — | — | — |
| USD/shares | $0.07 – $0.62 | — | $4.89 | $1.75 | -$0.72 | -$1.60 | -$1.54 | -$2.19 | -$1.40 | — | — | — |
| shares | — | — | 29.37M | 29.76M | 29.3M | 28.07M | 27.26M | 26.07M | 23.8M | 14.58M | 1.18M | 1.1M |
| shares | — | — | 29.76M | 30.54M | 29.3M | 28.07M | 27.26M | 26.07M | 23.8M | 14.58M | 1.18M | 1.1M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $175.02M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.25×
EV/EBIT
—
Medical Devices median 21.94×
P/E (TTM)
11.48×
Medical Devices median 27.77×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Operating Segment | $911,981,000 | $802,804,000 | $624,799,000 | $407,856,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $872,086,000 | $771,040,000 | $606,178,000 | $394,833,000 | $220,976,000 | $106,108,000 | $73,660,000 | $44,378,000 |
| Non Us | $39,895,000 | $31,764,000 | $18,621,000 | $13,023,000 | — | — | — | — |
| All Other Countries | — | — | — | — | $12,418,000 | $9,273,000 | $8,390,000 | — |
| Europe | — | — | — | — | — | — | — | $6,215,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Operating Segment | $50,954,000 | $36,083,000 | -$40,271,000 | -$47,592,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Operating Segment | 5.6% | 4.5% | -6.4% | -11.7% |
Key facts
CIK
1609550
CUSIP
457730109
13F (30d)
25 filings
20 filers
Visit website
Investor relations